Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

Open access
Vicent, S, López-Picazo, J M, Toledo, G, Lozano, M D, Torre, W, Garcia-Corchón, C, Quero, C, Soria, J-C, Martín-Algarra, S, Manzano, R G, Montuenga, L M·2004·British Journal of Cancer

Abstract

Activation of the ERK1/2 pathway is involved in malignant transformation both in vitro and in vivo. Little is known about the role of activated ERK1/2 in non-small cell lung cancer (NSCLC). The purpose of this study was to characterise the extent of the activation of ERK1/2 by immunohistochemistry in patients with NSCLC, and to determine the relationship of ERK1/2 activation with clinicopathological variables. Specimens from 111 patients with NSCLC (stages I-IV) were stained for P-ERK. Staining for epidermal growth factor receptor (EGFR) and Ki-67 was also performed. In all, 34% of the tumour specimens showed activation for ERK1/2, while normal lung epithelial tissue was consistently negative. There was a strong statistical correlation between nuclear and cytoplasmic P-ERK staining and advanced stages (P<0.05 and P<0.001, respectively), metastatic hilar or mediastinal lymph nodes (P<0.01, P<0.001), and higher T stages (P<0.01, P<0.001). We did not find correlation of nuclear or cytoplasmic P-ERK staining with either EGFR expression or Ki-67 expression. Total ERK1/2 expression was evaluated with a specific ERK1/2 antibody and showed that P-ERK staining was not due to ERK overexpression but rather to hyperactivation of ERK1/2. Patients with a positive P-ERK cytoplasmic staining had a significant lower survival (P<0.05). However, multivariate analysis did not show significant survival difference. Our study indicates that nuclear and cytoplasmic ERK1/2 activation positively correlates with stage, T and lymph node metastases, and thus, is associated with advanced and aggressive NSCLC tumours.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6601644

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 186

Metadata

Authors
Vicent, S., López-Picazo, J. M., Toledo, G., Lozano, M. D., Torre, W., Garcia-Corchón, C., Quero, C., Soria, J.-C., Martín-Algarra, S., Manzano, R. G., & Montuenga, L. M.
Venue
British Journal of Cancer
Published
2004-03
Volume
90
Issue
5
Pages
1047-1052
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1979328434
Cited by
186
References
1
FWCI
7.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. https://app.cochat.ai/papers/10.1038/sj.bjc.6601644
The paper
Vicent, S., López-Picazo, J. M., Toledo, G., Lozano, M. D., Torre, W., Garcia-Corchón, C., Quero, C., Soria, J.-C., Martín-Algarra, S., Manzano, R. G., & Montuenga, L. M. (2004). ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.